6365 results for "11+1双色球多少钱一注"

in 20.06 milliseconds.

• Transcriptome of (monocytes and dendritic cells ), from donor S4, replicate 1 patient

  Dataset EGAD00001009012

• Transcriptome of (monocytes and dendritic cells ), from donor S5, replicate 1 control

  Dataset EGAD00001009014

• Transcriptome of (monocytes and dendritic cells ), from donor S10, replicate 1 control

  Dataset EGAD00001009024

• Transcriptome of (monocytes and dendritic cells ), from donor S11, replicate 1 patient

  Dataset EGAD00001009026

• Transcriptome of (monocytes and dendritic cells ), from donor S12, replicate 1 patient

  Dataset EGAD00001009028

• Transcriptome of (monocytes and dendritic cells ), from donor S13, replicate 1 control

  Dataset EGAD00001009030

• WTCCC case-control study for Type 1 Diabetes

  WTCCC genome-wide case-control association study for Type 1 Diabetes (T1D) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.

  Study EGAS00000000014

• University of Bergen Rare Monogenic Autoimmune Syndrome (APS-1) Data Access Committee

  This is the DAC appointed by the University of Bergen for the datasets related to the study of APS-1 in the Department of Clinical Sciences . These data are from single cell transcriptomic analysis of expanded Tregs from patients with the rare monogenic autoimmune syndrome “APS-1” compared to healthy donors.

  Dac EGAC50000000081

• Transcriptome of (peripheral blood), from donor Sample A, replicate 1 Freezing replicates

  Freezing replicates

  Dataset EGAD00001010084

• Transcriptome of (peripheral blood), from donor Sample A, replicate 1 Technical replicates

  Technical replicates

  Dataset EGAD00001010082

• Nasal brushes analysis

  scRNA-seq samples from healthy and asthma donors part 1.

  Study EGAS00001006657

• High-Throughput LINE-1 Retrotransposon Discovery in Humans

  The aim of this study is to discover LINE-1 (L1) insertion sites present in humans that are absent from the reference genome sequence. We use the distinguishing nucleotide characteristics of human-specific L1 elements to resequence the L1 3' flanking regions thus locating the L1 insertion sites whether or not they are present in the reference genome assembly. In doing so, we have uncovered a higher than expected number of non-reference L1 insertions, an average of 152 insertions per individual. In addition, we find that any two individuals differ at an average of 285 sites with respect to presence or absence of L1 insertions in those sites, and use this to estimate the rate of retrotransposition in humans at 1 event per 140 live births (95% c.i. 1/95 to 1/270). We show that individual 'L1 profiles' recapitulate genetic ancestry as expected, and find that dimorphic insertions are more frequent in introns relative to fixed insertions.

  Study phs000273

• Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression

  Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease and to reveal uncharacterized aspects of tumor biology. Here we discover 121 unannotated prostate cancer-associated ncRNA transcripts (PCATs) by ab initio assembly of high-throughput sequencing of polyA+ RNA (RNA-Seq) from a cohort of 102 prostate tissues and cells lines. We characterized one ncRNA, PCAT-1, as a prostate-specific regulator of cell proliferation and show that it is a target of the polycomb repressive complex 2 (PRC2). We further found that patterns of PCAT-1 and PRC2 expression stratified patient tissues into molecular subtypes distinguished by expression signatures of PCAT-1-repressed target genes. Taken together, our findings suggest that PCAT-1 is a transcriptional repressor implicated in a subset of prostate cancer patients. These findings establish the utility of RNA-Seq to identify disease-associated ncRNAs that may improve the stratification of cancer subtypes.

  Study phs000443

• Stage-1 meta-analysis with GC correction

  Stage-1 meta-analysis with GC correction

  Dataset EGAD00001004800

• Targeted sequencing data and shallow whole genome sequencing data of Follicular lymphoma.

  Contain data of 2 studies 1: 82 nodal stage 1 FL cases and 139 stage III/IV cases 2: 44 watch and wait stage III/IV and 46 Immediate treatment stage III/IV targeted sequencing data of 369 genes and 12 translocation regions whole genome shallow sequencing data

  Study EGAS00001005755

• CRU303 GWAS Raw Data Batch 1 Controls

  Raw data files of samples in batch 1 of CRU303 GWAS

  Dataset EGAD00010001955

• CRU303 GWAS Called Data Batch 1

  Called genotypes of samples in batch 1 of CRU303 GWAS

  Dataset EGAD00010001951

• Chromatin remodeling enhances MAP3K8 expression in HAM: a key pathogenesis for therapeutic intervention

  Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy (HAM) is a debilitating neuroinflammatory disease with no available effective treatments. A hallmark of HAM is the transformation of HTLV-1-infected cells into T helper type 1 (Th1)-like cells, characterized by excessive interferon (IFN)-gamma production that drives chronic inflammation. However, the molecular mechanisms fuel this aberrant Th1-like transformation and sustained inflammation remain poorly understood. We hypothesized that HAM-characteristic chromatin remodeling plays a pivotal role in the overexpression of key genes driving inflammatory pathogenesis. Using transcriptomic analysis, chromatin accessibility profiling, and biomarker evaluations across HTLV-1-related diseases, we identify MAP3K8 as a key gene that defines the unique inflammatory profile of HAM. MAP3K8 overexpression promotes Th1-like differentiation and constitutively activates the MEK-ERK signaling pathway. Furthermore, we elucidate the mechanism by which HTLV-1 Tax, Fosl2, and c-Jun collaboratively induce HAM-characteristic chromatin remodeling at the enhancer region of the MAP3K8 locus. Crucially, we demonstrate that mitogen-activated protein kinase kinase (MEK) inhibitors effectively suppress the MAP3K8-MEK signaling cascade and significantly mitigated inflammatory pathogenesis in an ex vivo culture assay. Our findings provide critical insights into the virus-host interactions underpinning HAM and propose the MAP3K8-MEK-ERK axis as a promising therapeutic target for this challenging condition.

  Study JGAS000835

• CRU303 GWAS Raw Data Batch 1 Cases

  Raw data files of samples in batch 1 of CRU303 GWAS

  Dataset EGAD00010001954

• Transcriptome of (peripheral blood), from donor Sample A, replicate 1 FACS processing technical replicates

  FACS processing technical replicates

  Dataset EGAD00001010086

• Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

  Purpose: To evaluate the safety, efficacy, pharmacokinetics, pharmacodynamics, and biomarker data of linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies. Patients and Methods: In this phase 1/2 study, patients received once-daily (QD) linrodostat (part 1 [escalation], 25-400 mg; part 2 [expansion], 100 or 200 mg) plus nivolumab (480 mg every [Q] 4 weeks [W] or 240 mg Q2W) or triplet therapy (part 3, linrodostat 20-100 mg QD; nivolumab 360 mg Q3W or 480 mg Q4W; ipilimumab 1 mg/kg Q6W or Q8W). Endpoints included safety and efficacy (co-primary; parts 2, 3), pharmacokinetics, pharmacodynamics, biomarkers, and efficacy (part 1). Results: Fifty-five, 494, and 41 patients were enrolled in parts 1, 2, and 3, respectively. Linrodostat exposures exceeded predicted therapeutic target concentrations starting at 50 mg. Rates of grade 3/4 adverse events were 50.1%-63.4%. The maximum tolerated linrodostat dose was 200 mg; dose-limiting toxicities were primarily immune related. Responses were observed across different cohorts, study parts, and tumor types, particularly in immunotherapy-naive patients. Kynurenine decreased with linrodostat + nivolumab, regardless of response. In contrast, interferon gamma (IFN-γ) gene expression signature was associated with response; in nonmelanoma patients, a composite of low tryptophan 2,3-dioxygenase (TDO2) gene expression plus high IFN-γ signature was associated with response. Conclusions: Linrodostat + nivolumab ± ipilimumab demonstrated a manageable safety profile. Kynurenine changes supported IDO1 pathway inhibition but did not correlate with response. A composite biomarker of low TDO2 expression plus high IFN-γ gene expression may predict response to linrodostat + nivolumab.

  Study EGAS50000000710

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells - untreated) from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008057

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells - untreated) from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008037

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells - untreated) from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008047

• Targeted capture ctDNA Library CRCQV42Run021-16

  Targeted capture ctDNA Library CRCQV42Run021-16 from patient PBC0001470, plasma 1 month sample

  Dataset EGAD00001010438

• Acute myeloid leukemia sequencing data

  This study contains tumor DNA and RNA sequencing data for 1 AML patient

  Study EGAS00001006354

• Alpha1-Antitrypsin Deficiency Registry (AADR-BioLINCC)

  Data Access NOTE: Please refer to the “Authorized Access” section below for information about how access to the data from this accession differs from many other dbGaP accessions. Objectives: To characterize the clinical and laboratory course of patients with severe alpha 1-antitrypsin deficiency whether or not the patient is undergoing long-term augmentation therapy.Background: A hereditary disorder, patients with low serum levels of alpha-1-antitrypsin are at an increased risk for the early onset of emphysema. The only approved treatment for alpha-1-antitrypsin deficiency is augmentation therapy using a purified preparation of human alpha-1-antitryspin. Sample sizes for a randomized controlled clinical trial of augmentation therapy were determined to be infeasible; therefore, a multi-center registry was initiated in 1988 to explore the natural history of the disease and the relative efficacy of augmentation therapy in patients with a severe deficiency of alpha-1-antitrypsin.Participants: Eligible participants included individuals 18 years of age or greater for whom the Central Laboratory confirmed that the serum alpha 1-antitrypsin level is Conclusions: Participants receiving augmentation therapy had decreased mortality risk during follow-up. FEV1 decline among all participants did not differ by augmentation therapy; however, among participants with FEV1 35-49% predicted, FEV1 decline was significantly slower for participants on augmentation therapy than for those not receiving therapy. (Am J Respir Crit Care Med, 1998; 158:49-59)

  Study phs004187

• ChIP seq samples

  Dataset contains 12 ChIP-Seq samples sequenced on the Illumina NextSeq500 sequencer. 3 samples are control samples (HcAct-Chip 1,HcAct-Chip 2,HcAct-Imput 2) 9 samples are case samples (HcAct2DG-Chip 1,HcAct2DG-Chip 2,HcAct2DG-Imput 1,JIAAct-Chip1,JIAAct-Chip2,JIAAct-Imput2,JIAAct2DG-Chip1,JIAAct2DG-Chip2,JIAAct2DG-Imput2)

  Dataset EGAD50000001188

• Methylation and nucleosome occupancy studies on cell-free DNA using enzymatic cytosine conversion

  Raw sequencing data (PE, fastq.gz) from NovaSeq 6000 sequencing runs of: 1. Blood-derived cell-free DNA from six healthy controls, enzymatic cytosine conversion (between 1 and 3 replicates each) 2. Urine-derived cell-free DNA from three healthy controls, enzymatic cytosine conversion (between 1 and 3 replicates each) 3. Blood-derived cell-free DNA from six patients with acute or chronic kidney disease with/without other relevant organ dysfunction, enzymatic cytosine conversion (between 1 and 3 replicates each) 4. Urine-derived cell-free DNA from three patients with acute kidney disease, enzymatic cytosine conversion (between 1 and 3 replicates each) 5. Blood-derived cell-free DNA from three healthy controls, bisulfite cytosine conversion (single datasets) 6. Conventional whole-genome sequencing on genomic DNA of two healthy kidney donors for two of the studied patients (single datasets).

  Dataset EGAD00001006072

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Resveratrol from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008059

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Oligomycin from donor D2, replicate 1, glucose concentration 1mM

  Dataset EGAD00001008055

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Rotenone from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008061

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Oligomycin from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008063

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Oligomycin from donor D3, replicate 1, glucose concentration 1mM

  Dataset EGAD00001008065

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Resveratrol from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008067

• Transcriptome of human CD4+ T-lymphyocyte (regulatory-T-cells) treated with Resveratrol from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008069

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Resveratrol from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008071

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Resveratrol from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008039

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Rotenone from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008041

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Oligomycin from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008043

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Oligomycin from donor D1, replicate 1, glucose concentration 1mM

  Dataset EGAD00001008045

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Resveratrol from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008049

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Rotenone from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008051

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Oligomycin from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008053

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Oligomycin from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008087

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Rotenone from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008089

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Oligomycin from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008079

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Rotenone from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008081

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Oligomycin from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008083

• Transcriptome of human CD4+ T-lymphyocyte (naive-T-cells) treated with Rotenone from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008085